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Abstract
Objective Type D personality has been associated with
impaired health status in chronic heart failure (CHF), but
other psychological factors may also be important.
Aim To determine whether non-Type D patients with low
positive affect and Type D patients report lower health sta-
tus, compared with non-Type D patients with high positive
affect at 12-month follow-up in chronic heart failure.
Methods Consecutive CHF outpatients (n = 276) filled
out the Short Form-12 (health status) and Health Com-
plaints Scale (disease-specific complaints) at inclusion and
12-month follow-up, and the DS14 (Type D personality)
and positive affect (Global Mood Scale) at inclusion. Three
groups were composed: non-Type D patients without
anhedonia, non-Type D patients with anhedonia, and Type
D patients.
Results After controlling for demographic and clinical
confounders, and scores at inclusion, anhedonic non-Type
D patients reported lower mental health status (b = –.19,
P \ .004), and more feelings of disability (b = .10,
P = .04), marginally lower physical health status (b =
-.11, P = .07), and equal levels of cardiac symptoms
(b = .04, P = .43), when compared with non-Type D’s
without anhedonia. Type D patients reported lower levels of
impaired mental health status, more cardiac symptoms
and feelings of disability (-.31 \ b\ .17, all Ps \ .05).
A trend was shown for physical health status (b = -.11,
P = .09).
Conclusion Non-Type D patients low on positive affect
and Type D patients report lower levels of health status in
CHF, compared with non-Type D patients with high positive
affect. Future studies need to determine whether lack of
positive affect is associated with impaired clinical outcome.
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Introduction
Psychological risk factors have been acknowledged in the
onset and progression of coronary heart disease (CHD) [1].
Apart from the established detrimental effects of negative
emotions, there’s a growing interest in the role of positive
affect [2]. Positive and negative affect can be considered as
two independent systems, with positive affect not solely
being the opposite of negative affect [3], and the possibility
that both types of affect can be present simultaneously [4].
High positive affect can be described as a state of high
energy, full concentration, and pleasurable engagement,
whereas high negative affect can be described as the ten-
dency to report distress, discomfort, dissatisfaction, and
feelings of hopelessness over time and situations [5].
Positive affect has been shown to be protective for incident
hypertension [6], whereas the influence on incident CHD is
conflicting [7, 8]. In established CHD, high levels of positive
affect have been associated with less hospital readmissions [9],
whereas low levels of positive affect, also referred to as
anhedonia, increase the risk of major clinical events in patients
following coronary-artery stenting [10]. Conflicting findings
have been reported for associations between positive affect and
survival in CHD (e.g. [11–13]). Finally, positive affect has been
shown to be associated with the production of early inflam-
matory markers in a middle-aged community sample [14], and
systolic blood pressure in healthy non-smoking men [15].
In addition to positive affect, there is a growing interest in
the role of personality factors in cardiovascular diseases
(CVD). Type D personality (i.e., the combined tendency to
experience negative emotions and to inhibit the expression of
these emotions) is an emerging independent risk marker for
clinical outcome and impaired patient-centred outcomes in
cardiac disease (e.g., [16–18]). However, Type D personality
is not the only risk marker for impaired health outcomes in
CVD. Within those patients categorized as non-Type D,
there may also be some heterogeneity in terms of their risk of
adverse health outcomes. Within those patients categorized
as having no Type D personality, some subgroups of patients
may also report lower levels of health outcomes.
Therefore, the aim of the current study was to determine
whether non-Type D patients low on positive affect and
Type D patients, report lower levels of health status when
compared with non-Type D patients with high positive
affect at 12-month follow-up in chronic heart failure (CHF).
Method
Patient selection and procedure
Consecutive heart failure outpatients (n = 408) were
approached for participation by their treating cardiologist
or specialised heart failure nurse between January 2001 and
June 2007 at the outpatient clinics of the St. Elisabeth
Hospital, Tilburg, and TweeSteden Hospital, Tilburg and
Waalwijk, Tilburg, The Netherlands. Inclusion criteria
consisted of (1) left ventricular ejection fraction
(LVEF) B 40%, (2) age B 80 years, and (3) no hospitali-
sations in the month prior to inclusion in the study. Patients
were excluded from participation in case of (1) insufficient
knowledge of written or spoken Dutch language, (2) evi-
dent cognitive impairments, (3) chronic severe psychiatric
condition (except for depression or anxiety), and (4) pres-
ence of other life-threatening co-morbidities (e.g., cancer).
All patients were treated according to the most recent
guidelines for heart failure [19].
If patients agreed to participate, they were contacted by
the researcher by telephone within 2 weeks after their
outpatient visit. Patients filled out a set of standardized and
validated questionnaires at inclusion and at 12-month fol-
low-up at home and were asked to return the completed
questionnaire in a stamped, pre-addressed envelope.
Questionnaires were checked for completeness and in case
items were left open, participants were called or mailed a
copy of the questionnaires with the request to complete
these. Patients who did not return the questionnaires within
2 weeks received a reminder telephone call or letter.
A flow-chart of patient selection is provided in Fig. 1.
Patients eligible for participation  
visiting cardiology outpatient clinic  
n=408
Refused participation at inclusion  n=60
Died between baseline and follow-up n=23
Refused participation at follow-up  
n=27
Excluded at follow-upa
n=14
Unreachable by telephone
n=1
Too many missings on questionnairesb n=7
Included participants n=276
a
 because of comorbidities (e.g., diagnosis of dementia or cancer, heart transplant, or 
psychiatric problems). 
b
 i.e., >30% missing items on questionnaires 
Fig. 1 Flowchart of patient selection
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The response rate was 67.4% and final analyses were based
on 276 patients.
The study protocol was approved by the medical ethics
committee of both teaching hospitals. Participation was
voluntary. The study was conducted according to the
Helsinki Declaration, and every patient provided written
informed consent.
Measures
Demographic and clinical characteristics
Demographic variables included gender, age, educational
level, and marital status, and were assessed by means of
purpose designed questions in the questionnaire. Clinical
variables, obtained from the patients’ medical records,
consisted of LVEF, New York Heart Association (NYHA)
functional class, etiology of heart failure, current smoking
status, cardiac history (i.e., previous myocardial infarction
(MI), coronary artery bypass graft surgery (CABG), or
percutaneous coronary intervention (PCI)), history of
stroke or transient ischemic attack (TIA), diabetes, hyper-
cholesterolemia, hypertension, renal disease, chronic
obstructive pulmonary disease (COPD), and peripheral
arterial disease (PAD). In addition, information on pre-
scribed medications (i.e., beta-blockers, ACE inhibitors,
calcium antagonists, angiotensin receptor blockers (ARB),
spironolactone, nitrates, statins, aspirin, and diuretics) was
obtained from the patients’ medical records.
Type D personality
At inclusion, Type D personality was assessed by means of
the Type D scale (DS14) [20]. This 14-item questionnaire
consists of two subscales, Negative Affectivity (e.g., ‘I am
often down in the dumps’) and Social Inhibition (e.g., ‘I am
a closed kind of person’), each comprising 7 items. Items
are answered on a 5-point Likert scale, ranging from 0
(‘false’) to 4 (‘true’). A standardized cut-off score C10 on
both subscales is used to classify individuals with a Type D
personality [20]. The cut-off score of C10 for both sub-
scales has been confirmed as the most optimal by means of
Item Response Theory (IRT) in samples from the general
population, hypertensives, and CHD patients [21]. The
co-occurrence of Negative Affectivity and Social Inhibi-
tion, and not solely the presence of negative emotions,
predicted poor outcome following PCI [22]. Both subscales
have good internal validity (Negative Affectivity: Cron-
bach’s a = .88 and Social Inhibition: Cronbach’s a =
0.86), are stable over a 3-month period (r = 0.82/0.72),
and are independent of mood and health status [20]. The
stability of Type D personality during an 18-month period
has been demonstrated in a study in post-MI patients [23]
and shown not to be confounded by disease severity [23].
Positive affect
Positive affect was assessed at inclusion by means of the
Global Mood Scale (GMS) [24]. The positive affect sub-
scale consists of 10 mood items (e.g., ‘active’ or
‘dynamic’) that are scored on a five-point Likert scale
ranging from 0 (‘false’) to 4 (‘true’). Cronbach’s a for the
subscale is .91, and the test–retest reliability over a three-
month period is .57 [24]. The GMS positive affect score
was dichotomised using a median split (i.e., C19) for cat-
egorizing low and high levels of positive affect, i.e.,
anhedonia versus no anhedonia, respectively.
Health status
The Dutch version of the Short-Form Health Survey12
(SF-12) was administered to assess generic health status
[25, 26] at inclusion and at 12-month follow-up. This
generic instrument measures overall physical and mental
health status, as indicated by the Physical Component Scale
Summary (PCS) and the Mental Component Summary
(MCS) scores [27]. According to standard scoring proce-
dures, all scale scores were standardized to the general US
population (range [0–100], mean = 50, SD = 10), with
higher scores indicating better functioning. The SF-12 has
been demonstrated to be a reliable and valid instrument [25].
Cardiac symptoms and feelings of disability
The 24-item Health Complaints Scale (HCS), a disease-
specific questionnaire, was administered at inclusion to
assess cardiac symptoms and feelings of disability [28].
Both the symptom (e.g., ‘tightness of the chest’ and
‘feeling weak’) and the feelings of disability (e.g., ‘feeling
you are not able to do much’ and ‘worrying about your
health’) subscale comprise 12 items that are scored on a 4-
point Likert scale ranging from 0 (‘not at all’) to 4
(‘extremely’), with a score range from 0 to 48. A high score
on both subscales indicate higher levels of complaints. The
internal consistency of the HCS is good (.89\a\.91) and
the test–retest reliability has proven to be adequate
(r = .69) in cardiac patients [28, 29]. In the current sample,
Cronbach’s a for the symptom subscale and feelings of
disability subscale were .91 and .93, respectively.
Statistical analyses
Differences in demographic and clinical characteristics
were examined using the chi-square test for dichotomous
variables and analysis of variance (ANOVA) for
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continuous variables. Three groups were composed, strat-
ified by Type D personality and positive affect; i.e., a
low-risk group of non-Type D without anhedonia, an
intermediate risk group of non-Type D patients with
anhedonia, and a high-risk group of Type D patients.
Linear regression analyses (Enter method), with non-
Type D patients without anhedonia as the reference
category, were conducted to examine anhedonia and Type
D personality as predictors of impaired health status, car-
diac symptoms, and feelings of disability at 12-month
follow-up. In multivariable analyses, we adjusted for gen-
der, age, partner status (having a partner vs. having no
partner), lower educational level (primary schooling or
lower vs. secondary schooling and higher), current
Table 1 Patient characteristics stratified by Type D personality and positive affect
Total sample
(n = 276)
Non-Type D
High positive affecta
(n = 117)
Non-Type D
Low positive affect
(n = 103)
Type D
(n = 56)
P
Demographics
Females 23.9 (66) 21.4 (25) 28.2 (29) 18.2 (12) .44
Age, mean (SD) 65.9 (9.5) 64.3 (10.1) 66.5 (9.0) 68.0 (8.8) .04*
Having no partner 25.7 (71) 25.6 (30) 24.3 (25) 28.6 (16) .84
Low educational level 33.0 (91) 22.2 (26) 39.8 (41) 42.9 (24) .005**
Clinical variables
LVEF, mean (SD)b 31.8 (6.7) 32.3 (6.7) 31.6 (6.5) 31.2 (7.2) .56
NYHA-class III/IVc 33 (91) 28.6 (26) 37.9 (39) 46.4 (26) .003**
Ischemic etiology 41.3 (114) 41.0 (48) 39.8 (41) 44.6 (25) .84
Current smoking 22.5 (62) 25.6 (30) 24.3 (25) 12.5 (7) .13
Cardiac historyd 63.0 (174) 60.7 (71) 67.0 (69) 60.7 (34) .58
Stroke/TIA 15.2 (42) 15.4 (18) 20.4 (21) 5.4 (3) .04*
Diabetes mellitus 24.6 (68) 23.9 (28) 24.3 (25) 26.8 (15) .92
Hypercholesterolemia 54.7 (151) 55.6 (65) 52.4 (54) 57.1 (32) .83
Hypertension 34.1 (94) 34.2 (40) 34.0 (35) 33.9 (19) .99
Renal disease 10.5 (29) 7.7 (9) 11.7 (12) 14.3 (8) .37
COPDe 13.8 (38) 18.8 (22) 9.7 (10) 10.7 (6) .11
PADf 17 (47) 20.5 (24) 12.6 (13) 17.9 (10) .29
Medication
Beta-blockers 67.4 (186) 70.9 (83) 62.1 (64) 69.6 (39) .35
ACE-inhibitors 72.5 (200) 70.1 (82) 73.8 (76) 75.0 (42) .74
Calcium-antagonists 13.4 (37) 12.0 (14) 9.7 (10) 23.2 (13) .05*
ARBg 19.6 (54) 21.4 (25) 17.5 (18) 11 (19.6) .77
Spironolactone 20.3 (56) 22.2 (26) 18.4 (19) 19.6 (11) .78
Nitrates 27.2 (75) 22.2 (26) 27.2 (28) 37.5 (21) .11
Statins 54.7 (151) 58.1 (68) 48.5 (50) 58.9 (33) .28
Aspirin 39.5 (109) 38.5 (45) 38.8 (40) 42.9 (24) .85
Diuretics 74.6 (206) 69.2 (81) 73.8 (76) 87.5 (49) .04*
Results are presented as % (n), unless otherwise stated
a Reference group
b LVEF Left ventricular ejection fraction
c NYHA New York Heart Association functional class
d CABG, MI, or PCI
e COPD Chronic obstructive pulmonary disease
f PAD Peripheral arterial disease
g ARB Angiotensin receptor blockers
* P B .05
** P B .01
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smoking status, NYHA class (I–II vs. III–IV), LVEF,
stroke or TIA, COPD, statins, calcium antagonists,
diuretics, and health status at inclusion, cardiac complaints
and feelings of disability at inclusion. Covariates were
selected based on univariable analyses and the literature.
All statistical tests were two-tailed, and P \ .05 was
used to indicate statistical significance. Statistical analyses
were performed using SPSS 14.0 for Windows (SPSS Inc.,
Chicago, Illinois, USA).
Results
Responders versus non-responders
Respondents were more likely to be prescribed ACE-
inhibitors (P = .07), digoxin (P = .03), and spironolac-
tone (P = .04) than non-responders. Trends were also
found for comorbid COPD (P = .08) and nitrates
(P = .08), with respondents likely to have comorbid
COPD and to be prescribed nitrates when compared with
non-responders. No other differences emerged in demo-
graphic or clinical characteristics.
Patient characteristics
The prevalence of Type D personality was 20.2% in this
sample. Patient characteristics stratified by Type D status
and positive affect are presented in Table 1. Differences
emerged between groups with respect to age, educational
level, NYHA class, stroke/TIA, and prescription of calcium
antagonists, with Type D patients being older when com-
pared with non-Type D patients without anhedonia
(P = .04). In addition, Type D patients had a lower edu-
cational level (P = .005), were more often classified in
NYHA class III-IV (P = .003), prescribed calcium antag-
onists (P = .05), and diuretics (P = .04), but were less
likely to have experienced a stroke or TIA (P = .04).
Positive affect, Type D personality, and health status
Mean physical and mental health status scores at
12 months for non-Type D patients with anhedonia, non-
Type D patients with anhedonia and Type D patients are
presented in Fig. 2a (top).
In comparison with the reference group of non-Type D
patients without anhedonia, non-Type D patients with
anhedonia and Type D patients reported lower levels of
mental health status at 12-month follow-up (see Table 2;
left, top). After controlling for demographic and clinical
confounders, and mental health status at inclusion, both
anhedonic non-Type D patients and Type D patients
report lower levels of health status when compared with
non-Type D patients without anhedonia (see Table 2; left,
bottom). Further, being prescribed calcium-antagonists was
an independent predictor of better mental health status at
12-month follow-up. A trend was shown for history of
stoke or TIA to be independently associated with lower
levels of mental health status at 12-month follow-up (see
Table 2; left, bottom).
In univariable analyses, both non-Type D patients with
anhedonia and Type D patients reported lower levels of
physical health status at 12-months, compared with the
reference group of non-Type D patients without anhedonia
(see Table 2; right, top). In multivariable analyses, a trend
was shown for non-Type D patients with anhedonia and
Type D patients to report lower levels of physical health
status at 12-month follow-up, when compared with the
reference group (see Table 2; right, bottom). Further,
female gender, being prescribed statins or calcium-antag-
onists were independent predictors of lower physical health
status at follow-up. Better physical health status at inclu-
sion was an independent predictor of better physical health
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Type D (n=56)
Fig. 2 Mean health outcome scores at 12 months stratified by Type
D personality and positive affect
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status at follow-up. Finally, a trend was shown for having
no partner to be associated with lower physical health
status at 12-month follow-up (see Table 2; right, bottom).
Positive affect, Type D personality, cardiac symptoms
and feelings of disability
Mean scores on cardiac symptoms and feelings of dis-
ability at 12 months for non-Type D patients with anhe-
donia, non-Type D patients with anhedonia and Type D
patients are presented in Fig. 2b (bottom).
In univariable analyses, non-Type D patients with
anhedonia and Type D patients reported more cardiac
symptoms at 12-month follow-up, when compared with the
reference group of non-Type D patients without anhedonia
(Table 3; left, top). In multivariable analyses, Type D
remained associated with higher levels of cardiac symp-
toms, but the association between non-Type D patients
with anhedonia and higher levels of cardiac symptoms at
12-month follow-up was no longer significant. In addition,
higher LVEF and cardiac symptoms at inclusion were
independent predictors of more cardiac symptoms at 12-
month follow-up (Table 3; left, bottom).
Non-Type D patients with anhedonia and Type D
patients reported more feelings of disability at 12-months,
when compared with the reference group of non-Type D
patients without anhedonia, in univariable analyses
(Table 3; right, top). After controlling for demographic and
clinical variables, and scores at inclusion, both non-Type D
patients with anhedonia and Type D patients still reported
more feelings of disability at 12-month follow-up. Further,
higher LVEF and feelings of disability at inclusion were
independent predictors of higher levels of feelings of dis-
ability at 12-months. Finally, a trend was shown for higher
age to be independently associated with more feelings of
disability at 12-month follow-up (Table 3 right, bottom).
Discussion
In the present study, we identified group of CHF patients
reporting lower levels of health status at 12 months,
Table 2 Predictors of impaired health status at 12-month follow-up (SF12)
Mental component summary Physical component summary
b t P b t P
Univariable analyses
Non-Type D and low PAa -.25 -4.04 \.001* -.22 -3.49 .001***
Type Da -.34 -5.52 \.001*** -.26 -4.04 \.001***
Multivariable analyses
Non-Type D and low PAa -.19 -2.92 .004** -.11 -1.80 .07
Type Da -.31 -4.34 \.001*** -.11 -1.70 .09
Female gender -.03 -.49 .62 -.16 -2.88 .004**
Age -.01 -.10 .63 -.05 -.87 .38
Having no partner .03 .56 .58 -.09 -1.71 .09
Lower educational level -.007 -.11 .91 -.03 -.54 .59
Current smoking -.04 -.61 .54 -.08 -1.51 .13
NYHA class III-IV -.04 -.59 .56 .01 .17 .86
LVEF -.08 -1.21 .23 -.07 -1.22 .23
Stroke/TIA -.11 -1.88 .06 .003 .06 .95
COPD .06 1.07 .29 -.03 -.47 .64
Statins .04 .69 .49 -.15 -2.77 .006**
Calcium-antagonists .12 1.94 .05* -.11 -2.04 .04
Diuretics -.10 -1.57 .11 -.08 -1.50 .13
Health status at inclusion .10 1.66 .10 .37 6.07 \.001***
R2 .16 .31
PA Positive affect; NYHA New York Heart Association functional class; LVEF Left ventricular ejection fraction; COPD Chronic obstructive
pulmonary disease; TIA Transient ischemic attack
a Compared with the reference group of non-Type D patients high on positive affect
* P B .05
** P B .01
*** P B .001
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namely those patients classified as having no Type D
personality, but low on positive affect. This specific group
of anhedonic non-Type D patients were shown to report
lower levels of mental and physical health status, as well as
more feelings of disability at 12-month follow-up, when
compared with non-Type D patients high on positive affect.
Furthermore, Type D patients were shown to report lower
levels of health status, more cardiac symptoms, and more
feelings of disability, when compared with non-Type D
patients high on positive affect.
In this study the findings on the detrimental effects of
Type D personality on patient-centered outcomes in CHF
were confirmed [30, 31]. Furthermore, we were able to
identify a subgroup of anhedonic patients reporting lower
levels of patient-centred outcomes. Post-hoc analyses
demonstrated that these differences in patient-centred
outcomes between groups were not only statistically rel-
evant, but also clinically relevant, as effect sizes were
overall large to very large (Cohen’s d). CHF outpatients
with a Type D personality reported lower levels of
physical and mental health status at 12-month follow-up.
These findings are in line with those of Hu and colleagues
showing that older community dwelling persons diag-
nosed with chronic disease (i.e., arthritis, CVD, COPD, or
diabetes) high on positive affect and low on negative
affect had better mental and physical health status [32].
Other studies that have also shown that lack of positive
affect is associated with worse clinical outcome in
patients with established CAD [9, 10]. However, in the
current study we did not have information on hard med-
ical outcomes, like readmission rates and major adverse
clinical events.
Apart from psychological factors, demographic and
clinical characteristics were associated with impaired
health outcomes in the current study. Overall, demographic
and clinical factors were more likely to be related to
physical health status than to mental health status at 12-
months. For instance, we found female gender and having
no partner to be associated with lower levels of physical
health status, which has also been demonstrated by others
[33]. Nevertheless, the impact of marital status has not
received considerable attention, but there are indications
that single marital status and poor marital quality are
associated with mortality in CHF.
Table 3 Predictors of cardiac symptoms and feelings of disability at 12-month follow-up (HCS)
Cardiac symptoms Feelings of disability
b t P b t P
Univariable analyses
Non-Type D and low PAa .22 3.59 \.001** .23 3.82 \.001**
Type Da .39 6.42 \.001** .45 7.62 \.001
Multivariable analyses
Non-Type D and low PAa .04 .79 .43 .10 2.02 .04*
Type Da .11 2.11 .04* .17 3.22 .001**
Female gender -.006 -.15 .88 -.002 -.05 .96
Age .07 1.54 .13 .08 1.84 .07
Having no partner -.02 -.50 .62 -.03 -.76 .45
Lower educational level .06 1.42 .16 .005 .12 .91
Current smoking .02 .54 .59 .06 1.37 .17
NYHA class III–IV .008 .19 .85 .05 1.03 .30
LVEF .09 1.96 .05* .09 2.02 .04*
Stroke/TIA .009 .22 .83 .05 1.09 .28
COPD .01 .34 .74 .02 .43 .67
Statins -.006 -.14 .89 -.01 -.33 .74
Calcium-antagonists -.01 -.25 .81 -.02 -.50 .62
Diuretics .04 1.03 .31 .05 1.08 .28
Symptoms and feelings of disability at inclusion .69 14.83 \.001** .62 12.52 \.001**
R2 .58 .53
PA Positive affect; NYHA New York heart association functional class; LVEF Left ventricular ejection fraction; COPD Chronic obstructive
pulmonary disease; TIA Transient ischemic attack
a Compared with the reference group of non-Type D patients high on positive affect
* P B .05
** P B .001
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Limitations of the current study must be acknowledged.
First, the present study relied on self-reported outcomes.
Nevertheless, all instruments administered are standardized
measures that have been shown to be valid and reliable. In
addition, the evaluation of patient-centred outcomes is of
importance as there is a known discrepancy in physician
and patient ratings of functioning, with physicians tending
to underestimate the disabilities of patients [34]. Further,
the evaluation of health status is advocated by guidelines
for treatment [35, 36], since impaired health status is pre-
dictive of mortality in CHF [37, 38] and generally patients
report to prefer better health status over prolonged survival
[39]. Second, in the present study only patients visiting the
outpatient clinic were approached for participation. Con-
sequently, the results cannot be generalized to clinical heart
failure samples. In this study, levels of positive affect were
dichotomized. Future studies need to further explore
whether a dose-response relationship exists between levels
of positive affect and patient-centred outcomes. Further,
from this study no conclusions regarding causality can be
drawn, because of the study design. Finally, residual con-
founding might have affected the results from the present
study, although we adjusted for various confounders in
multivariable analyses. A strength of the current study
comprises the use of both generic as well as cardiac dis-
ease-specific instruments for the evaluation of health out-
comes. Future studies could include psychometrically
sound CHF-specific health status questionnaires, to spe-
cifically evaluate health status in this particular patient
group [40].
From a clinical point of view, the present study under-
lines the importance of evaluating psychological risk fac-
tors, and in particular the clustering of psychological risk
factors, as this enables the identification of different risk
groups. This has also been advocated by others [41]. Given
that impaired health status has been associated with poor
prognosis in CHF [37], non-Type D patients low on posi-
tive affect and patients with a Type D personality should be
identified in clinical practice, as they might need additional
support and adjunctive intervention in order to experience
health status levels comparable with other patients. Inter-
ventions might consist of improving skills to experience
more positive affect by means of cognitive-behavioral
therapy and mindfulness-based stress reduction. These
types of psychological treatment have shown to be bene-
ficial for improving positive affect in medically ill patients
[42, 43] and in older depressed patients at increased car-
diovascular risk [44].
In conclusion, we identified a specific group of CHF
outpatients at risk for reporting impaired health outcomes,
in the present study, namely those patients low on positive
affect, and not classified as having a Type D personality. In
addition, Type D patients also reported lower levels of
health status, when compared with the reference group.
Future studies are warranted to replicate the current and to
determine the associations between positive affect and hard
outcomes in CHF.
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